Cholesterol plaque in artery

Clinical Trial Analysis of PCSK9 Inhibitors: The Impact of Real-World Cardiovascular Outcomes

Program Overview

In this module of a Four-Part Expert Interview Series, Dr. Michael J. Blaha, along with Dr Christopher P. Cannon, course chair, will explore the role of PCSK9 inhibitors in the treatment of dyslipidemia patients and the impact of real-world cardiovascular outcomes. This discussion will aid physicians in providing optimal care in clinical practice.

Target Audience

Cardiologists, internists, and other healthcare professionals involved in the management of patients with dyslipidemia

Learning Objectives 

1.Analyze the role of PCSK9 Inhibitors in modern day clinical practice
2. Consider real-world impact of cardiovascular outcomes data when making treatment decisions for patients


Cannon Head ShotChristopher P. Cannon, MD
Director, Education, Cardiovascular Medicine Innovation
Cardiovascular Division, Brigham and Women’s Hospital
Professor of Medicine, Harvard Medical School
Boston, Massachusetts



Blaha HeadshotMichael J. Blaha, MD
Associate Professor of Medicine
Johns Hopkins School of Medicine
Director of Clinical Research
Ciccarone Center for the Prevention of Heart Disease
Baltimore, Maryland


Disclosures of Conflict of Interest

It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

FacultyRelationship Identified With:
Christopher P. Cannon, MDConsultant/Advisor: Alnylam Pharmaceuticals, Inc.; Amarin Corporation; Amgen Inc.; Boehringer Ingelheim; Bristol-Myers Squibb Company; Eisai Co., Ltd.; Janssen Global Services, LLC; Kowa Company, Ltd.; Merck & Co.; Pfizer Inc.; Regeneron; SanofiGrant/Research Support: Amgen Inc.; Boehringer Ingelheim; Bristol-Myers Squibb Company; Daiichi Sankyo Company Limited; Janssen Global Services, LLC; Merck & Co.
Michael J. Blaha, MD Consultant/Advisor: Aetna; Akcea Therapeutics; Amgen Inc.; Novo Nordisk; Regeneron; SanofiGrant/Research Support: Amgen Inc.

Planners, Managers, Reviewers

Timothy Hayes, MD, PhD; Emma Boring and Chelsey Benedek hereby state that they or their spouse/life partner do not have any financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.

Accreditation Statement

AcademicCME is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement

AcademicCME designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Financial Support

This activity has been supported by an independent educational grant from Amgen Inc.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and Amgen Inc. do not recommend the use of any agent outside of the labeled indications.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Method of Participation

1. Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
2. Complete the Pre-Activity Questions
3. Read or Review the activity content.
4. Complete the Post-Activity Test Questions and Evaluation.
5. Physicians who receive a grade of 66% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a CME Certificate.
6. All other participants who receive a grade of 66% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a Certificate of Participation.

CE Inquiries/Special Needs

For all CME inquiries or special needs, please contact [email protected].